Alphabet Inc. Takes Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Alphabet initiated a position in Autolus Therapeutics, purchasing 698,262 shares worth approximately $1.12 million, or about 0.26% of AUTL. Institutional investors collectively own 72.83% of the company.
• Analyst sentiment is generally positive, with Autolus carrying a “Moderate Buy” consensus rating and an average price target of $10.00; ratings range from Strong Buy to Sell.
• Autolus reported better-than-expected quarterly results, including an adjusted loss of $0.15 per share versus the $0.21 expected and revenue of $45.69 million versus $38.56 million estimated. The company remains a clinical-stage developer of engineered T-cell cancer therapies.

Alphabet Inc. bought a new position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 698,262 shares of the company's stock, valued at approximately $1,117,000. Autolus Therapeutics makes up about 0.0% of Alphabet Inc.'s holdings, making the stock its 28th biggest holding. Alphabet Inc. owned approximately 0.26% of Autolus Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AUTL. Marex Group plc bought a new position in shares of Autolus Therapeutics during the 2nd quarter valued at about $28,000. Independent Advisor Alliance bought a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $28,000. GAMMA Investing LLC increased its holdings in shares of Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock worth $25,000 after purchasing an additional 8,309 shares during the last quarter. SmartHarvest Portfolios LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $43,000. Finally, Waverly Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter worth about $37,000. Institutional investors own 72.83% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on AUTL shares. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday. Weiss Ratings raised Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday. Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday, April 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $10.00.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $2.28 on Tuesday. The company has a market capitalization of $606.84 million, a price-to-earnings ratio of -2.15 and a beta of 2.07. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.17 and a 12 month high of $2.43. The firm's 50-day moving average is $1.66 and its 200 day moving average is $1.58. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The business had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.8 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source